ReNeuron Group Plc (RENE) Earns “Buy” Rating from Stifel Nicolaus

Stifel Nicolaus reissued their buy rating on shares of ReNeuron Group Plc (LON:RENE) in a research report sent to investors on Thursday. They currently have a GBX 13 ($0.17) price target on the stock.

Separately, N+1 Singer reissued a corporate rating on shares of ReNeuron Group Plc in a research note on Tuesday, October 31st.

ReNeuron Group Plc (LON:RENE) traded down GBX 0.05 ($0.00) during midday trading on Thursday, hitting GBX 2.10 ($0.03). The stock had a trading volume of 2,000,000 shares, compared to its average volume of 1,880,000. ReNeuron Group Plc has a 12 month low of GBX 1.58 ($0.02) and a 12 month high of GBX 3.67 ($0.05).

ILLEGAL ACTIVITY NOTICE: “ReNeuron Group Plc (RENE) Earns “Buy” Rating from Stifel Nicolaus” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.themarketsdaily.com/2017/11/12/reneuron-group-plc-rene-earns-buy-rating-from-stifel-nicolaus.html.

About ReNeuron Group Plc

ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company’s products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP).

Receive News & Ratings for ReNeuron Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply